Article

Shaji Kumar on Later Lines of Treatment for Myeloma

Author(s):

Shaji Kumar

There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.

Shaji Kumar, professor of medicine, Division of Hematology, Mayo Clinic, provides an overview of later lines of therapy for patients with multiple myeloma.

There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.

Related Videos
Image of man with black hair.
Image of a man with dark hair and some facial hair.
Image of a man with blond facial hair.
Image of woman with blonde hair.
Image of a woman with long red hair.
Image of a man in a suit.
Image of woman with brown hair.
Image of a man with short hair, wearing a buttoned-up shirt.
Image of a man with short black hair.
Related Content
Illustration of woman with blonde hair.
November 20th 2024

What Patients with Breast Cancer Need to Know About Lymphedema Risk

Alex Biese
CURE® spoke with a physical therapist specializing in oncology to find out more about this condition some patients with cancer are at risk for.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Image of a woman with short blonde hair, wearing a colorful striped shirt.
November 19th 2024

Why Clinical Trials Don’t Have to Be Patients’ ‘Last Line of Defense’

Alex Biese
A patient with small cell lung cancer shared her clinical trial experience with CURE® and how she encourages other patients with cancer to enroll.
Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic
January 13th 2022

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.
Image of red blood cells.
November 18th 2024

Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma

Darlene Dobkowski, MA
Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be presented at an upcoming conference.
Illustration of a doctor speaking with a patient in a doctor's office.
November 12th 2024

QOL a Crucial Consideration During R/R Myeloma Treatment Decision-Making

Ashley Chan
Patients with relapsed or refractory multiple myeloma should consider quality of life with survival when choosing the most suitable treatment option.